FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138870012> ?p ?o ?g. }

• W2138870012 endingPage "77" @default.
• W2138870012 startingPage "70" @default.
• W2138870012 abstract "Study objectives Mometasone furoate dry powder inhaler (MF-DPI) [400 μg] is an inhaled corticosteroid (ICS) that is effective in the treatment of asthma. MF-DPI has a low potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis at its clinical dose. The effect of MF-DPI, 400 μg qd, on the HPA axis was compared to that of beclomethasone dipropionate (BDP) using hydrofluoroalkane (HFA) and chlorofluorocarbon (CFC) propellants via metered-dose inhalers (MDIs) twice daily. Design and interventions This randomized, third-party blind, parallel-group study compared the effects of MF-DPI 400 μg one puff qd in the morning (n = 18), HFA-BDP 200 μg two puffs MDI bid (n = 18), and CFC-BDP 400 μg two puffs MDI bid (n = 17) for 14 days on the area under the 24-h serum cortisol concentrations curve (AUC0–24) and on total 24-h urinary free cortisol excretion in mild asthmatic subjects. Effects on morning/evening peak expiratory flow (PEF) and on inhaled albuterol use were also assessed. Adverse events that occurred during or ≥ 30 days after the study were recorded. Results The mean decrease from baseline in the serum cortisol concentrations AUC0–24 in the MF-DPI group was significantly less than in either the HFA-BDP (p = 0.024) or the CFC-BDP (p = 0.011) groups. Decreases in serum cortisol concentrations AUC0–24 in the two BDP groups did not differ from one another. The MF-DPI group trended toward higher morning and evening PEF than either BDP group. Treatment-associated adverse events were reported by seven subjects in the MF-DPI group, vs one subject in the HFA-BDP and three subjects in the CFC-BDP groups; these were mild, and no subject discontinued treatment due to an adverse event. Conclusions Fourteen days of treatment with MF-DPI 400 μg qd was associated with a significantly lesser decrease in the serum cortisol concentrations AUC0–24 compared with HFA-BDP 200 μg MDI or CFC-BDP 400 μg MDI bid. Mometasone furoate dry powder inhaler (MF-DPI) [400 μg] is an inhaled corticosteroid (ICS) that is effective in the treatment of asthma. MF-DPI has a low potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis at its clinical dose. The effect of MF-DPI, 400 μg qd, on the HPA axis was compared to that of beclomethasone dipropionate (BDP) using hydrofluoroalkane (HFA) and chlorofluorocarbon (CFC) propellants via metered-dose inhalers (MDIs) twice daily. This randomized, third-party blind, parallel-group study compared the effects of MF-DPI 400 μg one puff qd in the morning (n = 18), HFA-BDP 200 μg two puffs MDI bid (n = 18), and CFC-BDP 400 μg two puffs MDI bid (n = 17) for 14 days on the area under the 24-h serum cortisol concentrations curve (AUC0–24) and on total 24-h urinary free cortisol excretion in mild asthmatic subjects. Effects on morning/evening peak expiratory flow (PEF) and on inhaled albuterol use were also assessed. Adverse events that occurred during or ≥ 30 days after the study were recorded. The mean decrease from baseline in the serum cortisol concentrations AUC0–24 in the MF-DPI group was significantly less than in either the HFA-BDP (p = 0.024) or the CFC-BDP (p = 0.011) groups. Decreases in serum cortisol concentrations AUC0–24 in the two BDP groups did not differ from one another. The MF-DPI group trended toward higher morning and evening PEF than either BDP group. Treatment-associated adverse events were reported by seven subjects in the MF-DPI group, vs one subject in the HFA-BDP and three subjects in the CFC-BDP groups; these were mild, and no subject discontinued treatment due to an adverse event. Fourteen days of treatment with MF-DPI 400 μg qd was associated with a significantly lesser decrease in the serum cortisol concentrations AUC0–24 compared with HFA-BDP 200 μg MDI or CFC-BDP 400 μg MDI bid." @default.
• W2138870012 created "2016-06-24" @default.
• W2138870012 creator A5002330992 @default.
• W2138870012 creator A5042458628 @default.
• W2138870012 creator A5046164327 @default.
• W2138870012 creator A5068738720 @default.
• W2138870012 creator A5089660470 @default.
• W2138870012 date "2005-07-01" @default.
• W2138870012 modified "2023-10-06" @default.
• W2138870012 title "Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects" @default.
• W2138870012 cites W1484010345 @default.
• W2138870012 cites W1554562511 @default.
• W2138870012 cites W1966669919 @default.
• W2138870012 cites W1984258710 @default.
• W2138870012 cites W1993452567 @default.
• W2138870012 cites W2002796983 @default.
• W2138870012 cites W2003273340 @default.
• W2138870012 cites W2028762287 @default.
• W2138870012 cites W2039022629 @default.
• W2138870012 cites W2046013253 @default.
• W2138870012 cites W2048065046 @default.
• W2138870012 cites W2059097798 @default.
• W2138870012 cites W2065554109 @default.
• W2138870012 cites W2071956297 @default.
• W2138870012 cites W2093035932 @default.
• W2138870012 cites W2109428979 @default.
• W2138870012 cites W2115125184 @default.
• W2138870012 cites W2124585444 @default.
• W2138870012 cites W2133301528 @default.
• W2138870012 cites W2149383913 @default.
• W2138870012 cites W2156080652 @default.
• W2138870012 cites W2158525975 @default.
• W2138870012 cites W2166793321 @default.
• W2138870012 cites W387031605 @default.
• W2138870012 doi "https://doi.org/10.1378/chest.128.1.70" @default.
• W2138870012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16002918" @default.
• W2138870012 hasPublicationYear "2005" @default.
• W2138870012 type Work @default.
• W2138870012 sameAs 2138870012 @default.
• W2138870012 citedByCount "29" @default.
• W2138870012 countsByYear W21388700122013 @default.
• W2138870012 countsByYear W21388700122014 @default.
• W2138870012 countsByYear W21388700122015 @default.
• W2138870012 countsByYear W21388700122016 @default.
• W2138870012 countsByYear W21388700122020 @default.
• W2138870012 crossrefType "journal-article" @default.
• W2138870012 hasAuthorship W2138870012A5002330992 @default.
• W2138870012 hasAuthorship W2138870012A5042458628 @default.
• W2138870012 hasAuthorship W2138870012A5046164327 @default.
• W2138870012 hasAuthorship W2138870012A5068738720 @default.
• W2138870012 hasAuthorship W2138870012A5089660470 @default.
• W2138870012 hasConcept C121332964 @default.
• W2138870012 hasConcept C126322002 @default.
• W2138870012 hasConcept C1276947 @default.
• W2138870012 hasConcept C178790620 @default.
• W2138870012 hasConcept C185592680 @default.
• W2138870012 hasConcept C19720800 @default.
• W2138870012 hasConcept C197934379 @default.
• W2138870012 hasConcept C2776042228 @default.
• W2138870012 hasConcept C2776178081 @default.
• W2138870012 hasConcept C2776476923 @default.
• W2138870012 hasConcept C2776804153 @default.
• W2138870012 hasConcept C2777419714 @default.
• W2138870012 hasConcept C2777714996 @default.
• W2138870012 hasConcept C2777992530 @default.
• W2138870012 hasConcept C2779017260 @default.
• W2138870012 hasConcept C2779146795 @default.
• W2138870012 hasConcept C2780261241 @default.
• W2138870012 hasConcept C2781348165 @default.
• W2138870012 hasConcept C42219234 @default.
• W2138870012 hasConcept C71315377 @default.
• W2138870012 hasConcept C71924100 @default.
• W2138870012 hasConceptScore W2138870012C121332964 @default.
• W2138870012 hasConceptScore W2138870012C126322002 @default.
• W2138870012 hasConceptScore W2138870012C1276947 @default.
• W2138870012 hasConceptScore W2138870012C178790620 @default.
• W2138870012 hasConceptScore W2138870012C185592680 @default.
• W2138870012 hasConceptScore W2138870012C19720800 @default.
• W2138870012 hasConceptScore W2138870012C197934379 @default.
• W2138870012 hasConceptScore W2138870012C2776042228 @default.
• W2138870012 hasConceptScore W2138870012C2776178081 @default.
• W2138870012 hasConceptScore W2138870012C2776476923 @default.
• W2138870012 hasConceptScore W2138870012C2776804153 @default.
• W2138870012 hasConceptScore W2138870012C2777419714 @default.
• W2138870012 hasConceptScore W2138870012C2777714996 @default.
• W2138870012 hasConceptScore W2138870012C2777992530 @default.
• W2138870012 hasConceptScore W2138870012C2779017260 @default.
• W2138870012 hasConceptScore W2138870012C2779146795 @default.
• W2138870012 hasConceptScore W2138870012C2780261241 @default.
• W2138870012 hasConceptScore W2138870012C2781348165 @default.
• W2138870012 hasConceptScore W2138870012C42219234 @default.
• W2138870012 hasConceptScore W2138870012C71315377 @default.
• W2138870012 hasConceptScore W2138870012C71924100 @default.
• W2138870012 hasIssue "1" @default.
• W2138870012 hasLocation W21388700121 @default.
• W2138870012 hasLocation W21388700122 @default.
• W2138870012 hasOpenAccess W2138870012 @default.
• W2138870012 hasPrimaryLocation W21388700121 @default.

• next